tiprankstipranks

Alkermes price target raised to $34 from $33 at BofA

BofA raised the firm’s price target on Alkermes (ALKS) to $34 from $33 and keeps a Neutral rating on the shares. The company’s Q4 report and FY25 guidance “offered no major surprises,” the analyst tells investors. Data in the second half for ALKS2680 in narcolepsy is the “key company catalyst” and the next quarterly update may provide a more detailed timeline for data readouts of the two ongoing studies, the analyst added.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue